

Special Issue

Advances in Influenza Virus Vaccines

Message from the Guest Editors

The current pandemic has greatly accelerated advances in vaccine research and production. The question that emerges at this point, however, is: Will these advances in vaccinology benefit other infectious diseases, other than COVID-19? In recent years, we have witnessed improvements in existing influenza vaccine technologies aiming to overcome problems such as possible egg adaptation and immunosenescence, triggered mainly by lower effectiveness of influenza vaccines against the A/H3N2 influenza virus. This Special Issue of *Vaccines* on “Advances in Influenza Virus Vaccines” aims to bring together the work of scientists that aim to further improve influenza vaccine technology in order to bring about greater vaccine effectiveness. Research as well as opinion papers are welcome.

Guest Editors

Dr. George Kassianos

Prof. Dr. Raul Ortiz De Lejarazu

Dr. Iván Sanz Muñoz

Dr. Ivan Aloysius

Deadline for manuscript submissions

closed (30 June 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/110067

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).